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The von Hippel-Lindau protein 
controls ciliogenesis
Th e tumor syndrome von Hippel-Lindau (VHL) disease is 
caused by heterozygous germline inactivation of the VHL 
tumor suppressor gene. Th e cardinal feature of this hereditary 
cancer syndrome is development of multiple vascular tumors 
(hemangioblastomas) in the central nervous system and 
retina combined with clear-cell carcinoma of the kidney and 
pheochromocytoma. VHL disease is an autosomal-dominant 
disorder, and tumor development in VHL disease is linked to 
somatic inactivation of the remaining wild-type VHL allele, 
leading to loss of the wild-type VHL gene product, VHL 
protein (pVHL). In the kidney, this event not only precipitates 
the development of clear-cell carcinoma but is also associated 
with the growth of premalignant renal cysts; the pathogenesis 
of cystic kidney disease in VHL disease patients is unknown. 
Over the last few years, the pathogenesis of other cystic 
kidney diseases has been linked to the monocilia of kidney 
cells. Cilia are highly conserved organelles that project from 
the surfaces of many cells. Th e essential structure of renal 
monocilia consists of nine peripheral microtubule doublets 
forming the axoneme and surrounded by a membrane lipid 
bilayer that is continuous with the plasma membrane. Cilia 
are sensory organelles and have been shown to be involved 
in mechanosensation, photoperception, and osmosignaling. 
Th e assembly and maintenance of cilia are mediated by 
intrafl agellar transport, a bidirectional microtubule-based 
transport system.
In a recent study, Schermer et al. demonstrated that 
pVHL localizes to the monocilia of kidney cells and controls 
ciliogenesis. Knock-down of pVHL impeded the formation 
of cilia in mouse inner medullary collecting duct kidney 
cells, whereas the expression of pVHL in VHL-negative 
renal cancer cells rescued the ciliogenesis defect. Using 
green fl uorescent protein-tagged end-binding protein 1 to 
label microtubule plus ends, these authors found that pVHL 
does not aff ect the microtubule growth rate but is needed to 
orient the growth of microtubules toward the cell periphery, a 
prerequisite for the formation of cilia.
A role of pVHL in regulating ciliogenesis has previously 
been documented and, together with these results, could 
explain why VHL disease patients can develop polycystic 
kidney disease. Although much is known about the role 
of pVHL in tumorigenesis at the molecular level, the 
pathogenesis of premalignant kidney cysts in VHL disease 
patients has remained elusive, and the fi nding that pVHL 
plays a critical role in ciliogenesis sheds new light on the 
pathogenesis of premalignant kidney cysts in VHL disease 
patients. (J Cell Biol 2006; 175: 547–554)
Juan Oliver
Angiotensin II causes hypertension 
and cardiac hypertrophy through 
its receptors in the kidney
Despite decades of scrutiny, the precise pathogenesis of 
essential hypertension has been diffi  cult to delineate. 
Guyton and his associates suggested that defective handling 
of sodium by the kidney and consequent dysregulation of 
body fl uid volumes is a requisite, fi nal common pathway in 
hypertension pathogenesis. Th e powerful capacity of this 
pathway to modulate blood pressure is illustrated by the 
elegant studies of Lift on and associates showing that virtually 
all of the mendelian disorders with major impact on blood 
pressure homeostasis are caused by genetic variants aff ecting 
salt and water reabsorption by the distal nephron. However, 
other studies have suggested that primary vascular defects 
may cause hypertension by impacting peripheral resistance 
without direct involvement of renal excretory functions.
Among the various regulatory systems that impact blood 
pressure, the renin–angiotensin system has a key role. 
Inappropriate activation of the system, as in renal artery 
stenosis, leads to profound hypertension and cardiovascular 
 pVHL is localized to cilia of Madin-Darby canine kidney cells. pAb, 
polyclonal antibody; mAb, monoclonal antibody.
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morbidity. Moreover, in patients with essential hypertension, 
who typically lack overt signs of renin activation, inhibitors of 
the system eff ectively reduce blood pressure, suggesting that 
dysregulation of the renin–angiotensin system contributes to 
their elevated blood pressure.
Th e eff ects of angiotensin II to increase blood pressure are 
mediated by type I (AT1) angiotensin receptors, and these 
receptors are expressed in a variety of organ systems thought 
to play key roles in blood pressure homeostasis, including the 
heart, kidney, blood vessels, adrenal glands, and cardiovascular 
control centers in the brain. For example, stimulation of AT1 
receptors in the vasculature causes potent vasoconstriction 
and, in the adrenal cortex, causes release of aldosterone that 
in turn promotes sodium reabsorption in the distal nephron. 
In the brain, intraventricular injection of angiotensin II 
causes a dramatic pressor response that is also mediated by 
AT1A receptors. In the kidney, activation of AT1 receptors is 
associated with renal vasoconstriction and antinatriuresis. 
Nevertheless, whether angiotensin actions in these individual 
tissue sites contribute in vivo to the pathogenesis of 
hypertension and its complications is not clear.
To address this question, Crowley et al. used a kidney 
cross-transplantation strategy to separate the actions of 
AT1 receptor pools in the kidney from those in systemic 
tissues. Kidney transplantation was carried out between 
genetically matched wild-type mice and mice homozygous for 
a targeted disruption of the Agtr1a gene locus encoding the 
AT1A receptor. Th e AT1A receptor is the major AT1 receptor 
isoform in the mouse and the closest mouse homologue to 
the human AT1 receptor gene. Th e authors found that renal 
AT1 receptors are required for the development of angiotensin 
II-dependent hypertension and cardiac hypertrophy. Th at 
is, when AT1 receptors are eliminated from the kidney, the 
residual repertoire of systemic, extrarenal AT1 receptors is 
not suffi  cient to induce hypertension or cardiac hypertrophy. 
Th ese fi ndings demonstrate the critical role of the kidney 
in the pathogenesis of hypertension and its cardiovascular 
complications. Th ey also show that cardiac hypertrophy 
depends on blood pressure elevation rather than expression 
of AT1 receptors in the heart. Finally, they suggest that the 
major mechanism of action of inhibitors of angiotensin in 
hypertension is attenuation of angiotensin II eff ects in the 
kidney. (Proc Natl Acad Sci USA 2006; 103: 17985–17990)
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Long-lasting arrest of murine 
polycystic kidney disease with a 
cyclin-dependent kinase inhibitor
Polycystic kidney diseases (PKDs) are primarily characterized 
by the growth of fl uid-fi lled cysts in renal tubules, leading 
to end-stage renal disease. Mutations in the PKD1 or PKD2 
gene lead to autosomal-dominant PKD (ADPKD), a slowly 
developing adult form. Autosomal-recessive PKD results 
from mutations in the PKHD1 gene, aff ecting newborn 
infants and progressing very rapidly. No eff ective treatment is 
currently available for these diseases. All proteins known to be 
disrupted in PKD were recently localized to the primary cilia. 
Because ciliary functions seem to include cell-cycle regulation, 
disruption of proteins associated with cilia may directly aff ect 
the cell cycle and proliferation, resulting in cystic disease.
Bukanov et al. reasoned that the dysregulated cell cycle 
may be the most proximal cause of cystogenesis, and that 
intervention targeted at this point could provide signifi cant 
therapeutic benefi t for PKD. In a recent article, the authors 
examined the eff ect of treatment with (R)-roscovitine, a potent 
cyclin-dependent kinase (CDK) inhibitor, on the slowly 
progressive renal cystic disease in jck mice. Development of 
PKD in the jck mice resembles that of human disease in many 
ways, with cysts developing in multiple nephron segments 
and with more aggressive disease in males. (R)-Roscovitine, 
currently in clinical trials as an anticancer agent, inhibits 
Cdk2–cyclin E as well as Cdk7–cyclin H, Cdk9–cyclin T1, and 
Cdk5–p35–p25.
Th e authors found that treatment with (R)-roscovitine 
eff ectively arrested cystic disease in jck as well as cpk mouse 
models of PKD. Continuous daily administration of the 
drug was not required to achieve effi  cacy; pulse treatment 
provided a robust, long-lasting eff ect, indicating potential 
clinical benefi ts for a lifelong therapy. Molecular studies of 
the mechanism of action revealed eff ective cell-cycle arrest, 
transcriptional inhibition, and attenuation of apoptosis. Th e 
authors also found that (R)-roscovitine was active against 
cysts originating from diff erent parts of the nephron, a 
desirable feature for the treatment of ADPKD, in which cysts 
form in multiple nephron segments. Th ese results indicate 
that inhibition of CDK is a new and eff ective approach to the 
treatment of PKD in mice, and they highlight the therapeutic 
potential for cell-cycle inhibition for the treatment of PKD in 
humans. (Nature 2006; 444: 949–952)
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(R)-Roscovitine effectively attenuates disease progression in cpk mice.
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